McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Quick facts
Marketed products
- Methylphenidate extended-release; Atomoxetine · Psychiatry / Neurology
Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity, while atomoxetine is a selective norepinephrine reuptake inhibitor.
Phase 3 pipeline
- methylphenidate hydrochloride extended-release tablets · Attention deficit hyperactivity disorder (ADHD)
Methylphenidate hydrochloride is a central nervous system stimulant that works by increasing the levels of dopamine and norepinephrine in the brain.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. portfolio CI brief
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. pipeline updates RSS
Frequently asked questions about McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
What are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.'s marketed drugs?
Top marketed products include Methylphenidate extended-release; Atomoxetine.
What is McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.'s pipeline?
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. has 1 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include methylphenidate hydrochloride extended-release tablets.
Related
- Methylphenidate extended-release; Atomoxetine · Psychiatry / Neurology
- Sector hub: All tracked pharma companies